Viewing nowCombinationHyduang Duo Extended Release Tablet 25/1000 mg (Empagliflozin, Metformin)
Empagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202501553 · Approved 2025.06.23 · Insurance code 670609550
Improvement of blood glucose control in adults with type 2 diabetes
This medication is used as an adjunct to diet and exercise for improvements in blood sugar control in adult patients with type 2 diabetes. It is particularly effective for patients whose blood sugar is not adequately controlled. Additionally, caution is advised in patients with established cardiovascular disease; therefore, guidance from a healthcare professional should be strictly followed. This medication should be used considering blood sugar management and cardiovascular safety.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this drug 10/1000 mg extended-release or 25/1000 mg extended-release once daily. Patients taking this drug 5/1000 mg extended-release or 12.5/1000 mg extended-release should take 2 tablets together once daily. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.
This medication is used in diabetes treatment and contains two ingredients that assist in blood sugar control. However, it should not be used in patients with impaired kidney function or certain serious conditions. Particularly, if kidney function is moderately impaired or worse, taking this medication may pose health risks, so patients should consult a doctor. Furthermore, this medication should be discontinued in the presence of severe infections, dehydration, heart failure, or acute myocardial infarction. Hypoglycemic symptoms may occur during treatment, so caution is needed when used with insulin or other hypoglycemic agents. Kidney and liver functions should be regularly monitored for abnormalities during treatment. Also, gastrointestinal disorders, urinary tract infections, genital infections, and increased urination may occur, so patients should promptly inform their physician if such symptoms arise. This medication can cause a rare but serious side effect called lactic acidosis, so immediate medical attention is required if symptoms such as vomiting, abdominal pain, weakness, or difficulty breathing appear. It is advisable for pregnant women, those who may become pregnant, and nursing women not to take this medication. Elderly patients or those at risk of decreased fluid levels should be more cautious when taking this medication and should be closely monitored for dehydration and cardiovascular irregularities. This medication must be taken strictly according to a doctor's prescription and guidance, and potential interactions with other medications should also be considered. When swallowing the tablets, they should not be crushed or chewed; they should be swallowed whole, and the tablet coating passing in the stool is normal. In case of overdose, serious side effects may occur, so appropriate treatment should be sought immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.
Light yellow, oval, bi-convex extended release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.